Format

Send to

Choose Destination
Lancet. 1999 Jan 2;353(9146):57-62.

Leukotriene-receptor antagonists.

Author information

1
Department of Clinical Pharmacology & Therapeutics, Ninewells Hospital and Medical School, University of Dundee, UK. b.j.lipworth@dundee.uk

Abstract

Leukotriene-receptor antagonists are the first novel class of antiasthma drugs to become available over the past three decades. They have an unique profile in that they are a hybrid of an anti-inflammatory and bronchodilator drug, and they can be taken as a tablet once or twice daily. The published data with leukotriene-receptor antagonists such as montelukast or zafirlukast show good antiasthmatic activity over a wide spectrum of asthma severity either as monotherapy or with inhaled steroids. Another potential spin-off of leukotriene-receptor antagonists is that they also seem to be effective in treating allergic rhinitis, which commonly coexists in patients with asthma. Here I overview the clinical pharmacology of leukotriene antagonists and appraise the published data from clinical trials, and look at the appropriate position of these agents in asthma management guidelines.

PMID:
10023966
DOI:
10.1016/S0140-6736(98)09019-9
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center